Overexpression of BMI-1 is associated with poor prognosis in cervical cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 4, 2012, Pages

  Tong, Yong Qing ^a   Liu, Bei ^b   Zheng, Hong Yun ^a   He, Yu Juan ^b   Gu, Jian ^a   Li, Feng ^a   Li, Yan ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Biomarker; BMI 1; Cervical cancer; Metastasis; Prognosis

Indexed keywords

BMI1 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UTERINE CERVIX CANCER; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84870360196     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01564.x     Document Type: Article

References (27)

1. Saslow D, Runowicz CD, Solomon D etal. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362.
2. Villa LL. Assessment of new technologies for cervical cancer screening. Lancet Oncol 2008; 9: 910-911.
3. Chauhan SC, Jaggi M, Bell MC, Verma M, Kumar D. Epidemiology of human papilloma virus (HPV) in cervical mucosa. Methods Mol Biol 2009; 471: 439-456.
4. Chen YC, Hunter DJ. Molecular epidemiology of cancer. CA Cancer J Clin 2005; 55: 45-54; quiz 57.
5. Dall P, Herrmann I, Durst B etal. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 2005; 54: 51-60.
6. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005; (Suppl.): 17-23.
7. Takihara Y. Role of polycomb-group genes in sustaining activities of normal and malignant stem cells. Int J Hematol 2008; 87: 25-34.
8. Yu J, Rhodes DR, Tomlins SA etal. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663.
9. Hahn MA, Hahn T, Lee DH etal. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008; 68: 10280-10289.
10. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-784.
11. Alkema MJ, Wiegant J, Raap AK, Berns A, van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet 1993; 2: 1597-1603.
12. Dimri GP, Martinez JL, Jacobs JJ etal. The BMI-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002; 62: 4736-4745.
13. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 2008; 21: 583-590.
14. Yang J, Chai L, Liu F etal. BMI-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A 2007; 104: 10494-10499.
15. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364-6369.
16. Vrzalikova K, Skarda J, Ehrmann J etal. Prognostic value of BMI-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 2008; 134: 1037-1042.
17. Tong YQ, Liu B, Huang J etal. BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma. Cancer Biol Ther 2008; 7: 340-344.
18. Silva J, Garcia V, Garcia JM etal. Circulating BMI-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 2007; 9: R55.
19. Cui H, Hu B, Li T etal. BMI-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 2007; 170: 1370-1378.
20. Steele JC, Torr EE, Noakes KL etal. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 2006; 95: 1202-1211.
21. Zhang X, Wang CX, Zhu CB etal. Overexpression of BMI-1 in uterine cervical cancer: correlation with clinicopathology and prognosis. Int J Gynecol Cancer 2010; 20: 1597-1603.
22. Min L, Dong-Xiang S, Xiao-Tong G, Ting G, Xiao-Dong C. Clinicopathological and prognostic significance of BMI-1 expression in human cervical cancer. Acta Obstet Gynecol Scand 2011; 90: 737-745.
23. Dutton A, Woodman CB, Chukwuma MB etal. BMI-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007; 109: 2597-2603.
24. Silva J, Garcia JM, Pena C etal. Implication of polycomb members BMI-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res 2006; 12: 6929-6936.
25. Choi YJ, Choi YL, Cho EY etal. Expression of BMI-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat 2008; 113 83-93.
26. Wang H, Pan K, Zhang HK etal. Increased polycomb-group oncogene BMI-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 535-541.
27. Liu JH, Song LB, Zhang X etal. BMI-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008; 97: 267-272.